Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Other Operating Expenses (2016 - 2025)

Rein Therapeutics filings provide 3 years of Other Operating Expenses readings, the most recent being $28.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses fell 22.43% year-over-year to $28.7 million, compared with a TTM value of $28.7 million through Dec 2025, down 22.43%, and an annual FY2025 reading of $28.7 million, down 22.43% over the prior year.
  • Other Operating Expenses hit $28.7 million in Q4 2025 for Rein Therapeutics, down from $37.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $37.0 million in Q4 2024, with the low at $28.7 million in Q4 2025.